Financhill
Buy
59

COR Quote, Financials, Valuation and Earnings

Last price:
$291.07
Seasonality move :
7.02%
Day range:
$286.76 - $292.45
52-week range:
$214.77 - $296.65
Dividend yield:
0.73%
P/E ratio:
41.31x
P/S ratio:
0.19x
P/B ratio:
248.30x
Volume:
1.1M
Avg. volume:
2M
1-year change:
26.71%
Market cap:
$56.3B
Revenue:
$294B
EPS (TTM):
$7.03

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
COR
Cencora
$75.8B $4.10 9.59% 57.95% $297.49
BUDZ
Weed
-- -- -- -- --
CAH
Cardinal Health
$55.3B $2.15 0.69% 108.11% $144.87
LAB
Standard BioTools
$40.1M -$0.04 -11.95% -85.19% $2.38
MCK
McKesson
$94.2B $9.83 19.22% 19.81% $709.65
PNPL
Pineapple
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
COR
Cencora
$290.43 $297.49 $56.3B 41.31x $0.55 0.73% 0.19x
BUDZ
Weed
$0.03 -- $3.9M 180.00x $0.00 0% --
CAH
Cardinal Health
$145.53 $144.87 $35.2B 27.15x $0.51 1.39% 0.16x
LAB
Standard BioTools
$1.11 $2.38 $420.7M -- $0.00 0% 2.25x
MCK
McKesson
$706.77 $709.65 $88.6B 32.36x $0.71 0.39% 0.27x
PNPL
Pineapple
$0.0629 -- $4.6M -- $0.00 0% 30.91x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
COR
Cencora
97.3% 0.081 18.65% 0.51x
BUDZ
Weed
-- -1.086 -- --
CAH
Cardinal Health
164.81% 0.200 26.51% 0.46x
LAB
Standard BioTools
0.06% -0.535 0.05% 4.95x
MCK
McKesson
162.58% 0.870 11.1% 0.46x
PNPL
Pineapple
-- 2.419 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
COR
Cencora
$2.6B $807.5M 21.96% 155.22% 0.84% -$2.8B
BUDZ
Weed
-- -$92.7K -- -- -- -$19.7K
CAH
Cardinal Health
$1.9B $530M 53.16% -- 0.99% -$499M
LAB
Standard BioTools
$21.9M -$29.7M -32.61% -36.54% -64.16% -$17.4M
MCK
McKesson
$3.3B $1.3B 67.6% -- 1.36% -$2.6B
PNPL
Pineapple
-- -- -- -- -- --

Cencora vs. Competitors

  • Which has Higher Returns COR or BUDZ?

    Weed has a net margin of 0.6% compared to Cencora's net margin of --. Cencora's return on equity of 155.22% beat Weed's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    COR
    Cencora
    3.14% $2.50 $8.5B
    BUDZ
    Weed
    -- -$0.00 --
  • What do Analysts Say About COR or BUDZ?

    Cencora has a consensus price target of $297.49, signalling upside risk potential of 2.43%. On the other hand Weed has an analysts' consensus of -- which suggests that it could fall by --. Given that Cencora has higher upside potential than Weed, analysts believe Cencora is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    COR
    Cencora
    9 6 0
    BUDZ
    Weed
    0 0 0
  • Is COR or BUDZ More Risky?

    Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison Weed has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.517%.

  • Which is a Better Dividend Stock COR or BUDZ?

    Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.73%. Weed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Weed pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios COR or BUDZ?

    Cencora quarterly revenues are $81.5B, which are larger than Weed quarterly revenues of --. Cencora's net income of $488.6M is higher than Weed's net income of -$95.9K. Notably, Cencora's price-to-earnings ratio is 41.31x while Weed's PE ratio is 180.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus -- for Weed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    COR
    Cencora
    0.19x 41.31x $81.5B $488.6M
    BUDZ
    Weed
    -- 180.00x -- -$95.9K
  • Which has Higher Returns COR or CAH?

    Cardinal Health has a net margin of 0.6% compared to Cencora's net margin of 0.72%. Cencora's return on equity of 155.22% beat Cardinal Health's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    COR
    Cencora
    3.14% $2.50 $8.5B
    CAH
    Cardinal Health
    3.51% $1.65 $4.7B
  • What do Analysts Say About COR or CAH?

    Cencora has a consensus price target of $297.49, signalling upside risk potential of 2.43%. On the other hand Cardinal Health has an analysts' consensus of $144.87 which suggests that it could fall by -0.45%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    COR
    Cencora
    9 6 0
    CAH
    Cardinal Health
    9 5 0
  • Is COR or CAH More Risky?

    Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison Cardinal Health has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.768%.

  • Which is a Better Dividend Stock COR or CAH?

    Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.73%. Cardinal Health offers a yield of 1.39% to investors and pays a quarterly dividend of $0.51 per share. Cencora pays 27.58% of its earnings as a dividend. Cardinal Health pays out 58.57% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios COR or CAH?

    Cencora quarterly revenues are $81.5B, which are larger than Cardinal Health quarterly revenues of $55.3B. Cencora's net income of $488.6M is higher than Cardinal Health's net income of $400M. Notably, Cencora's price-to-earnings ratio is 41.31x while Cardinal Health's PE ratio is 27.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus 0.16x for Cardinal Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    COR
    Cencora
    0.19x 41.31x $81.5B $488.6M
    CAH
    Cardinal Health
    0.16x 27.15x $55.3B $400M
  • Which has Higher Returns COR or LAB?

    Standard BioTools has a net margin of 0.6% compared to Cencora's net margin of -72.93%. Cencora's return on equity of 155.22% beat Standard BioTools's return on equity of -36.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    COR
    Cencora
    3.14% $2.50 $8.5B
    LAB
    Standard BioTools
    46.89% -$0.09 $472M
  • What do Analysts Say About COR or LAB?

    Cencora has a consensus price target of $297.49, signalling upside risk potential of 2.43%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 113.96%. Given that Standard BioTools has higher upside potential than Cencora, analysts believe Standard BioTools is more attractive than Cencora.

    Company Buy Ratings Hold Ratings Sell Ratings
    COR
    Cencora
    9 6 0
    LAB
    Standard BioTools
    2 1 0
  • Is COR or LAB More Risky?

    Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.443%.

  • Which is a Better Dividend Stock COR or LAB?

    Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.73%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios COR or LAB?

    Cencora quarterly revenues are $81.5B, which are larger than Standard BioTools quarterly revenues of $46.7M. Cencora's net income of $488.6M is higher than Standard BioTools's net income of -$34.1M. Notably, Cencora's price-to-earnings ratio is 41.31x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus 2.25x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    COR
    Cencora
    0.19x 41.31x $81.5B $488.6M
    LAB
    Standard BioTools
    2.25x -- $46.7M -$34.1M
  • Which has Higher Returns COR or MCK?

    McKesson has a net margin of 0.6% compared to Cencora's net margin of 0.92%. Cencora's return on equity of 155.22% beat McKesson's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    COR
    Cencora
    3.14% $2.50 $8.5B
    MCK
    McKesson
    3.45% $6.95 $5.3B
  • What do Analysts Say About COR or MCK?

    Cencora has a consensus price target of $297.49, signalling upside risk potential of 2.43%. On the other hand McKesson has an analysts' consensus of $709.65 which suggests that it could grow by 0.41%. Given that Cencora has higher upside potential than McKesson, analysts believe Cencora is more attractive than McKesson.

    Company Buy Ratings Hold Ratings Sell Ratings
    COR
    Cencora
    9 6 0
    MCK
    McKesson
    10 3 0
  • Is COR or MCK More Risky?

    Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

  • Which is a Better Dividend Stock COR or MCK?

    Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.73%. McKesson offers a yield of 0.39% to investors and pays a quarterly dividend of $0.71 per share. Cencora pays 27.58% of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios COR or MCK?

    Cencora quarterly revenues are $81.5B, which are smaller than McKesson quarterly revenues of $95.3B. Cencora's net income of $488.6M is lower than McKesson's net income of $879M. Notably, Cencora's price-to-earnings ratio is 41.31x while McKesson's PE ratio is 32.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus 0.27x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    COR
    Cencora
    0.19x 41.31x $81.5B $488.6M
    MCK
    McKesson
    0.27x 32.36x $95.3B $879M
  • Which has Higher Returns COR or PNPL?

    Pineapple has a net margin of 0.6% compared to Cencora's net margin of --. Cencora's return on equity of 155.22% beat Pineapple's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    COR
    Cencora
    3.14% $2.50 $8.5B
    PNPL
    Pineapple
    -- -- --
  • What do Analysts Say About COR or PNPL?

    Cencora has a consensus price target of $297.49, signalling upside risk potential of 2.43%. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Cencora has higher upside potential than Pineapple, analysts believe Cencora is more attractive than Pineapple.

    Company Buy Ratings Hold Ratings Sell Ratings
    COR
    Cencora
    9 6 0
    PNPL
    Pineapple
    0 0 0
  • Is COR or PNPL More Risky?

    Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison Pineapple has a beta of 36.643, suggesting its more volatile than the S&P 500 by 3564.318%.

  • Which is a Better Dividend Stock COR or PNPL?

    Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.73%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios COR or PNPL?

    Cencora quarterly revenues are $81.5B, which are larger than Pineapple quarterly revenues of --. Cencora's net income of $488.6M is higher than Pineapple's net income of --. Notably, Cencora's price-to-earnings ratio is 41.31x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.19x versus 30.91x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    COR
    Cencora
    0.19x 41.31x $81.5B $488.6M
    PNPL
    Pineapple
    30.91x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is down 19.35% over the past day.

Buy
65
MYRG alert for May 2

MYR Group [MYRG] is up 3.13% over the past day.

Sell
35
FTAI alert for May 2

FTAI Aviation [FTAI] is up 6.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock